At Emergent CDMO, we’re committed to bringing what’s out on the horizon into clearer focus. Our distinct expertise and experience offers our clients an advantage in the development and manufacturing of their next generation therapies, which in turn gives them the potential to help patients in entirely new - and profoundly important - ways.
If mRNA therapies are at the heart of your science, you'll be able to capitalize on our lipid-based formulation development and manufacturing capabilities for mRNA, as well as other active pharmaceutical ingredients (APIs) requiring lipid encapsulation.
For over 20 years, we have been working with lipid-based formulations. We have decades of expertise in manufacturing complex API formulations, and we currently support the development, tech transfer, manufacturing, and fill/finish of liposomes and lipid nanoparticles (LNP), including LNP-mRNA.
Our foundational infrastructure and capabilities allow us to support out clients' needs from early phase to commercial scale LNP-mRNA and other API lipid-based formulations and fill/finish.
If you are interested in working with Emergent, want to find out more information about our CDMO services, or would like to have us contact you for any reason, please use this web form to send us your information or questions.